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Misidentifications of Burkholderia pseudomallei as Burkholderia cepacia by Vitek 2 have occurred. Multidimensional scaling
ordination of biochemical profiles of 217 Malaysian and Australian B. pseudomallei isolates found clustering of misidentified B.
pseudomallei isolates fromMalaysian Borneo. Specificity of B. pseudomallei identification in Vitek 2 and potentially other auto-
mated identification systems is regionally dependent.
Burkholderia pseudomallei is a saprophytic soil bacterium thatcauses melioidosis, a disease endemic in northern Australia
and Southeast Asia affecting humans and animals (1). The clinical
presentations of melioidosis range from skin infections without
sepsis to disseminated infection with sepsis and high mortality.
Pneumonia is present in around half of cases, and chronic infec-
tions, relapsed disease, and activation from latency are all recog-
nized (1, 2).
Confirmation of diagnosis of melioidosis requires a positive
culture of B. pseudomallei from clinical samples such as blood,
sputum, urine, pus, joint aspirate, or swabs from throat or rectum
(1). B. pseudomallei has been identified by combining the com-
mercial API 20NE biochemical kit (bioMérieux) with a simple
screening system involving Gram stain, oxidase reaction, typical
growth characteristics, and resistance to gentamicin (3). Suscep-
tibility to amoxicillin-clavulanate (AMC) has also been used to
differentiate B. pseudomallei from Burkholderia cepacia, which is
resistant to AMC (4). Unfamiliarity with B. pseudomallei and
problems with inaccurate species identification using some auto-
mated commercial biochemical identification systems have re-
sulted in laboratoriesmisidentifying the bacteriumas aPseudomo-
nas or other Burkholderia species (5–9). Confirmation of B.
pseudomallei identity by real-time PCR of DNA extracted from
cultured bacterial colonies is increasingly the standard for many
laboratories (10). Various genetic targets have been published for
PCR identification of B. pseudomallei from bacterial cultures and
also for direct detection fromclinical samples, with a recent review
showing the type III secretion system (TTS1)-orf2 assay to be su-
perior in detecting B. pseudomallei directly from clinical speci-
mens (11). Apart from molecular methods, B. pseudomallei from
cultures can also be confirmed by antigen detection assays, such as
latex agglutination (12). More recently, matrix-assisted laser de-
sorption ionization–time of flight mass spectrometry (MALDI-
TOFMS) has been adapted to identify cultured bacteria based on
protein fingerprint profiles (13).
A particular problem has been themisidentification of B. pseu-
domallei as Burkholderia cepacia by the Vitek 2 automated bio-
chemical system (bioMérieux) (5–8).B. cepacia belongs to a group
of 17 phenotypically and genotypically similar species which form
the B. cepacia complex, with B. cepacia specifically noted as an
opportunistic pathogen infecting and causing progressive pulmo-
nary deterioration in patients with cystic fibrosis (14, 15). Other
organisms that have been reportedly misidentified by the Vitek 2
system include Candida albicans being misidentified as Gram-
negative bacilli (16) and Candida parapsilosis being misidentified
as Candida famata (17).
We have compared the Vitek 2 system biochemical profiles of
68 confirmed B. pseudomallei clinical strains from hospitals in
Sabah and Sarawak, Malaysian Borneo, with 149 B. pseudomallei
and 18 B. cepacia isolates from the Royal Darwin Hospital (RDH)
in Northern Territory, Australia. One isolate per patient was ana-
lyzed. All isolates were collected between September 2010 and
June 2012, except for 17 isolates collected in 1994 from Sabah.
All isolates were subcultured on horse blood agar (HBA) be-
fore testing was performed on the Vitek 2 according to the man-
ufacturer’s instructions (bioMérieux). The Vitek 2 system utilizes
a panel of biochemical and enzymatic tests which results in a bio-
chemical profile that is compared against the manufacturer’s bac-
terial taxa database. All B. pseudomallei isolates were confirmed by
both real-time PCR targeting the well-validated B. pseudomallei
TTS1 (10) and by a latex agglutination test (12). Of the isolates
from Sarawak, 15/43 (35%) had been initially identified as B. ce-
pacia by the Vitek 2 system but were subsequently confirmed as B.
pseudomallei by both the TTS1 real-time PCR and the latex agglu-
tination test (Table 1). These 15 patients were fromhospitals from
different regions in Sarawak, none had cystic fibrosis, and me-
lioidosis was suspected clinically, with a diversity of clinical pre-
sentations, including subcutaneous infection, community-ac-
quired pneumonia, and sepsis. Only 2/25 B. pseudomallei isolates
from Sabah and 3/149 B. pseudomallei isolates from Darwin were
misidentified as B. cepacia (Table 1).
Using Primer version 6 (Primer-E Ltd., PlymouthMarine Lab-
oratory, United Kingdom), we performed a nonmetric multidi-
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mensional scaling (nMDS) ordination on the Euclidean distance
resemblance matrix of the Vitek 2 biochemical profiles of these
235 isolates. The nMDS (stress value of 0.19) showed a distinct
clustering of the 15 B. pseudomallei isolates from Sarawak that
were misidentified as B. cepacia (Fig. 1A). The nMDS ordination
also revealed a tight clustering of the correctly identified B. pseu-
domallei isolates regardless of country of origin, while the B. cepa-
cia isolates were more diverse (Fig. 1A and C). A permutation-
based, nonparametric analysis of similarities (ANOSIM)
confirmed this finding, with strong evidence that the biochemical
profiles of the misidentified B. pseudomallei isolates were distinct
from correctly identified B. pseudomallei (R statistic of 0.345, P
0.001).
An analysis of similarity percentages (SIMPER) calculating the
average contribution of each biochemical test to the overall ob-
served dissimilarity between clusters revealed that, in particular,
two enzymatic tests, the -N-acetyl-glucosaminidase (BNAG)
and -N-acetyl-galactosaminidase (NAGA), which hydrolyze
polysaccharides, were distinct between correctly and misidenti-
fied B. pseudomallei isolates. A total of 88% of correctly identified
B. pseudomallei isolates contained BNAG substrates resulting in a
positive test as opposed to 13% of misidentified isolates. This is
TABLE 1 Number of isolates tested with the Vitek 2 system
Sample origin
Total no. of B.
pseudomallei
isolatesa
Total no. of B.
cepacia isolates
tested
No. of B. pseudomallei
isolates correctly identified
as B. pseudomalleib,e
No. of isolates with
low discriminationc,e
No. of B. pseudomallei
isolates misidentified
as B. cepaciad,e
No. of B. cepacia
isolates correctly
identifiede
Sabah, Malaysian Borneo 25 Not done 22 (88) 1 (4) 2 (8) Not done
Sarawak, Malaysian Borneo 43 Not done 23 (53) 5 (12) 15 (35) Not done
Darwin, Australia 149 18 146 (98) 0 3 (2) 18 (100)
a Positive by TTS1 and agglutination tested.
b With a 90 to 99% probability of being B. pseudomallei.
c Low discrimination between B. cepacia and B. pseudomallei.
d With a 90 to 99% probability of being B. cepacia.
e Numbers in parentheses refer to the percentages of total isolates of the same state/country origin.
FIG 1 Nonmetric multidimensional scaling (nMDS) ordination on the Euclidean distance resemblance matrix of the Vitek 2 biochemical profile of 235 B.
pseudomallei and B. cepacia isolates from Australia and Malaysian Borneo. (A) Samples were identified as either B. pseudomallei, B. cepacia, B. pseudomallei
misidentified as B. cepacia, or isolates with low discrimination; (B) the bubble size reflects the presence (large) or absence (small) of BNAG substrate in an isolate;
(C) analysis based on isolates from both countries, Australia andMalaysia; (D) the bubble size reflects the presence (large) or absence (small) of NAGA substrate
in an isolate. Abbreviations: Bps, B. pseudomallei; Bcep, B. cepacia; Bcep misID, B. pseudomalleimisidentified as B. cepacia; BNAG, -N-acetyl-glucosaminidase;
NAGA, -N-acetyl-galactosaminidase.
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also evident in Fig. 1B and D. The exopolysaccharide (EPS) poly-
-(1-6)-N-acetylglucosamine (PNAG) is a substrate of the en-
zymeBNAGand is produced byBurkholderia spp. (18). PNAGhas
been reported to be an important component in biofilm forma-
tion inBurkholderia species, potentially contributing tomultidrug
resistance (18).N-Acetylgalactosamine, a derivative ofNAGA, has
also been documented as one of the basic components for EPS of
B. pseudomallei (19). The implications for virulence and immune
response of these different biochemical profiles remains uncer-
tain, but it has been suggested that the amount of capsular poly-
saccharide in B. pseudomallei compared to that in other Burkhold-
eria species may well contribute to its relative virulence (20).
As an environmental bacterium adapted to a diverse range of
tropical and subtropical habitats globally, B. pseudomallei is
known to harbor a vast intraspecies genomic diversity as a result of
high recombination frequency (21). It is therefore not surprising
that the biochemical database of the Vitek 2 system performs vari-
ably based on geographical location. That there was 98% accuracy
for the recentAustralian strains tested in this study shows substan-
tial improvement since prior studies (5, 6). The Sarawak data are
supported by the recent report from China of the same misiden-
tification in a case of melioidosis imported from Malaysia (8).
In conclusion, clinicians and laboratory scientists need to be
aware of continuing potential misidentification of B. pseudomallei
as B. cepacia by the Vitek 2 automated biochemical identification
system, especially in patients with suspected melioidosis acquired
in exotic locations, such as Malaysian Borneo. Similar difficulties
are likely to be encountered with other automated identification
systems, such as MALDI-TOF MS, as they are increasingly devel-
oped and utilized for patients infected in diverse geographical lo-
cations. PCR using validated targets (11) and ultimately whole-
genome sequencing can confirm correct identification of species.
Alternatively, for laboratories with limited resources, a combina-
tion of latex agglutination andAMCsusceptibility testing assists in
distinguishing B. pseudomallei from B. cepacia (4).
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